Suppr超能文献

男男性行为人群中 HIV 感染者肛门高危型人乳头瘤病毒感染的发生率、清除率及其影响因素。

Incidence and clearance of anal high-risk Human Papillomavirus infection and their risk factors in men who have sex with men living with HIV.

机构信息

STI/HIV Unit, San Gallicano Dermatological Institute IRCCS, Via Elio Chianesi 53, 00144, Rome, Italy.

Pathology Department, Regina Elena National Cancer Institute IRCCS, Via Elio Chianesi 53, 00144, Rome, Italy.

出版信息

Sci Rep. 2022 Jan 7;12(1):184. doi: 10.1038/s41598-021-03913-5.

Abstract

HIV-infected men who have sex with men (MSM) display the highest prevalence of anal infection by high-risk Human Papillomaviruses (hrHPVs) and incidence of anal carcinoma. Anal specimens were genotyped by the Linear Array. Incidence and clearance of anal infection by hrHPVs, hrHPVs other than HPV16, low-risk HPVs, and four individual types (6,11,16,18) were estimated using a two-state Markov model. Determinants for incidence and clearance were assessed by logistic regression. Overall, 204 individuals were included (median age 42 years, IQR = 34-49). For hrHPVs, incidence and clearance rates were 36.1 × 1000 person-months (p-m) (95% CI 23.3-56.5) and 15.6 × 1000 p-m (95% CI 10.7-23.3), respectively. HPV16 showed a higher incidence than HPV18 (10.2 vs. 7.2 × 1000 p-m). Its clearance was more than twofold lower than that of HPV18 (30.1 vs. 78.2 × 1000 p-m). MSM receiving cART displayed a 68% to 88% decrease in risk of acquiring hrHPVs, hrHPVs other than HPV16, HPV16, and HPV18 (adjusted Hazard Ratio [aHR] 0.13, 95% CI 0.02-0.67; aHR 0.22, 95% CI 0.06-0.78; aHR 0.32, 95% CI 0.12-0.90; aHR 0.12, 95% CI 0.04-0.31, respectively) than patients not treated. A nadir CD4 + count < 200 cells/mm significantly reduced the clearance of hrHPVs other than HPV16 (aHR 0.39, 95% CI 0.17-0.90). cART use reduces the risk of acquiring anal infection by hrHPVs.

摘要

HIV 感染者与男性发生性行为(MSM)表现出最高的高危型人乳头瘤病毒(hrHPV)肛门感染流行率和肛门癌发病率。通过线性阵列对肛门标本进行基因分型。采用两状态马尔可夫模型估计 hrHPV、HPV16 以外的 hrHPV、低危型 HPV 以及四种单独类型(6、11、16、18)的肛门感染发生率和清除率。使用逻辑回归评估发病和清除的决定因素。总体而言,纳入了 204 名个体(中位年龄 42 岁,IQR=34-49)。对于 hrHPV,发病率和清除率分别为 36.1×1000 人月(95%CI 23.3-56.5)和 15.6×1000 人月(95%CI 10.7-23.3)。HPV16 的发病率高于 HPV18(10.2 比 7.2×1000 人月)。其清除率比 HPV18 低两倍多(30.1 比 78.2×1000 人月)。接受 cART 的 MSM 感染 hrHPV、HPV16 以外的 hrHPV、HPV16 和 HPV18 的风险降低了 68%至 88%(调整后的危险比[aHR]0.13,95%CI 0.02-0.67;aHR 0.22,95%CI 0.06-0.78;aHR 0.32,95%CI 0.12-0.90;aHR 0.12,95%CI 0.04-0.31),而未接受治疗的患者风险更高。CD4+计数最低点<200 个细胞/mm 显著降低了 HPV16 以外的 hrHPV 清除率(aHR 0.39,95%CI 0.17-0.90)。cART 的使用降低了感染高危型肛门 HPV 的风险。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验